Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

Our robust, validated and approved protocol for DC manufacturing forms the basis for a harmonized procedure to produce cancer vaccines, which paves the way for larger multi-center clinical trials.